Overview: Immune Deficiency CD4 Panel
Introduction: The Immune Deficiency CD4 Panel is a diagnostic tool designed to assess CD4 cell population using whole blood samples. In India, CD4 lymphopenia is hallmark of HIV/AIDS (~2.4 million affected) and primary immunodeficiencies, with CD4 count guiding ART initiation (<350 cells/μL) and opportunistic infection prophylaxis. High morbidity from under-monitoring in rural/low-SES HIV patients, limited flow labs, delayed ART leading to AIDS-defining illnesses or mortality. Per immunology practices aligned with NACO and ICMR guidelines, the test employs flow cytometry for CD4 count, percentage, total lymphocytes, CD3 count, and T-cell profile over 1-2 days with high accuracy, valuable for HIV staging and PID evaluation. This diagnostic falls under immune profiling and targets HIV-positive patients or those with recurrent infections, addressing accurate detection to guide prophylaxis and therapy. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise CD4 assessment and reducing AIDS complications. Its whole blood-based approach ensures reliable enumeration.
Other Names: Imm Def CD4 Pnl.
FDA Status: FDA approved, CLIA certified for hematology/immunology, compliant with 2025 standards.
Historical Milestone: CD4 flow standard; in India, scaled under NACO ART programs.
Purpose: The test assesses 5 parameters including CD4 count to guide immune deficiency evaluation, monitor HIV/PID, inform prophylaxis.
Test Parameters: 1. CD4 Count, 2. CD4 Percentage, 3. Total Lymphocytes, 4. CD3 Count, 5. T-Cell Profile.
Pretest Condition: No fasting required; patients should have HIV or infection history.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow).
Medical History: Patients should provide details on HIV status, ART, infections.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of low CD4 including opportunistic infections, benefits of monitoring, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Low CD4 indicates advanced immunodeficiency, necessitating specialist input.
Specialist Consultation: HIV specialists or immunologists should be consulted for management.
Additional Supporting Tests: HIV viral load, Ig levels for confirmation.
Test Limitations: Requires viable cells; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, HIV/PID Studies India 2023.
